Search Within

Howard Scher

Formats
  1. Journal Article (626)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (7)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1133)
  2. Genitourinary Oncology Service (1133)
  3. Solid Tumor Oncology Division (1133)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (112)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (11)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1133)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study
    Journal Article

    Basch, E.; Iasonos, A.; McDonough, T.; Barz, A.; Culkin, A.; Kris, M. G.; Scher, H. I.; Schrag, D.
    Lancet Oncology (2006)

    Fulltext@MSK | Save
  • Hyperplastic and malignant diseases of the prostate
    Book Section

    Scher, H. I.
    In Kasper, D. L.; Braunwald, E.; Fauci, A. S.; Hauser, S. L.; Longo, D. L.; Jameson, J. L. (Eds.) Harrison's Principles of Internal Medicine. 16th ed (2005)

    Fulltext@MSK | Save
  • Bladder and renal cell carcinomas
    Book Section

    Scher, H. I.; Motzer, R. J.
    In Kasper, D. L.; Braunwald, E.; Fauci, A. S.; Hauser, S. L.; Longo, D. L.; Jameson, J. L. (Eds.) Harrison's Principles of Internal Medicine. 16th ed (2005)

    Fulltext@MSK | Save
  • Cancer of the prostate
    Book Section

    Scher, H. I.; Leibel, S. A.; Fuks, Z.; Cordon-Cardo, C.; Scardino, P. T.
    In DeVita, V. T.; Hellman, S.; Rosenberg, S. A. (Eds.) Cancer: Principles and Practice of Oncology. 7th ed (2005)

    Fulltext@MSK | Save
  • The clinical significance of a PSA nadir > 0.2 to patients with a rising post-operative or post-radiation PSA treated with androgen deprivation
    Meeting Abstract

    Stewart, A. J.; Scher, H.; Chen, M. H.; McLeod, D.; Carroll, P.; Moul, J.; D'Amico, A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin)
    Meeting Abstract

    Solit, D. B.; Egorin, M.; Kopil, C.; Delacruz, A.; Shaffer, D.; Slovin, S.; Morris, M.; Kelly, W. K.; Rosen, N.; Scher, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • The men's cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state
    Meeting Abstract

    Slovin, S. F.; Carducci, M. A.; Beekman, K. W.; Pili, R.; Eicher, C.; Kelly, W. K.; Morris, M. J.; Shaffer, D.; Eisenberger, M.; Scher, H. I.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • 2-MPPA, a selective inhibitor of PSMA, delays prostate cancer growth and attenuates taxol-induced neuropathy in mice
    Meeting Abstract

    She, Y.; Tang, Z.; Lapidus, R. G.; Wozniak, K. M.; Scher, H. I.; Slusher, B. S.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A phase I/II trial to assess tolerability and efficacy of RAD-001 with gefitinib in patients with glioblastoma multiforme and castrate metastatic prostate cancer
    Meeting Abstract

    Shaffer, D. R.; Abrey, L.; Beekman, K.; Morris, M.; Eicher, C.; Kelly, W. K.; Slovin, S.; Solit, D.; Rosen, N.; Scher, H. I.
    EJC Supplements (2005)

    Fulltext@MSK | Save